Rosen Law Firm Files Securities Fraud Lawsuit Against ADMA Biologics
Rosen Law Firm has initiated a securities fraud lawsuit against ADMA Biologics. Investors are urged to contact the law firm by the August 10, 2026 deadline.
The Rosen Law Firm has filed a securities class action lawsuit against ADMA Biologics, Inc., on behalf of investors who purchased its securities between August 9, 2024, and March 25, 2026. The firm is seeking lead plaintiffs and has set August 10, 2026, as a crucial deadline for those wishing to participate.
The lawsuit alleges that ADMA Biologics and its executives made materially false and misleading statements or failed to disclose critical information. These allegations include undisclosed related-party transactions, the use of channel stuffing to artificially inflate revenue, and inadequate internal controls. The complaint contends that these misrepresentations misled investors about the company's business operations and financial prospects.
Rosen Law Firm, a global investor rights law firm, is encouraging investors who sustained losses to come forward. The firm highlights its experience in securities class actions and its track record of recovering assets for investors. Participation in the class action involves no out-of-pocket fees for investors, operating under a contingency fee arrangement.
Investors who purchased ADMA Biologics securities during the specified class period are advised to contact Rosen Law Firm for more information. Any investor wishing to serve as lead plaintiff must file a motion with the court by the August 10, 2026 deadline. The firm emphasizes the importance of selecting qualified counsel with proven experience in such litigation.